NCT01148407

Brief Summary

Blood samples on persons with cancer will be sampled for angiogenic, metastatic and coagulation proteins.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jun 2010

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2010

Completed
20 days until next milestone

First Submitted

Initial submission to the registry

June 21, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

June 22, 2010

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2012

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2013

Completed
Last Updated

April 22, 2011

Status Verified

April 1, 2011

Enrollment Period

2.2 years

First QC Date

June 21, 2010

Last Update Submit

April 21, 2011

Conditions

Cancer

Keywords

breast cancerplateletsmetastatic cancermalignancy

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with a malignancy diagnosis.

You may qualify if:

  • Patients with a diagnosis of malignancy

You may not qualify if:

  • Patients taking aspirin, NSAIDs, warfarin or platelet inhibitor therapy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Vermont/Fletcher Allen Health Care

Burlington, Vermont, 05401, United States

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

plasma, serum and platelet activated blood samples

MeSH Terms

Conditions

NeoplasmsBreast NeoplasmsNeoplasm Metastasis

Condition Hierarchy (Ancestors)

Neoplasms by SiteBreast DiseasesSkin DiseasesSkin and Connective Tissue DiseasesNeoplastic ProcessesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Chris E Holmes, MD PhD

    University of Vermont

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Chris E Holmes, MD, PhD

CONTACT

802-656-0302ceholmes@uvm.edu

Study Design

Study Type
observational
Sponsor Type
OTHER

Study Record Dates

First Submitted

June 21, 2010

First Posted

June 22, 2010

Study Start

June 1, 2010

Primary Completion

August 1, 2012

Study Completion

August 1, 2013

Last Updated

April 22, 2011

Record last verified: 2011-04

Locations

US(1)